Initial Statement of Beneficial Ownership (3)
July 08 2022 - 06:00PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP
OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Lazar David
E. |
2. Date of Event Requiring Statement
(MM/DD/YYYY)
7/6/2022
|
3. Issuer Name and Ticker or Trading
Symbol TITAN PHARMACEUTICALS INC [TTNP] |
(Last)
(First)
(Middle)
VILLA 1, 14-43RD STREET, JUMEIRAH 2 |
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director ___X___
10% Owner
_____ Officer (give title
below) _____
Other (specify below)
|
(Street)
DUBAI, C0 00000
(City)
(State)
(Zip)
|
5. If Amendment, Date Original
Filed(MM/DD/YYYY)
|
6. Individual or Joint/Group
Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially
Owned
|
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock, par value $0.001 |
1421133 |
D (1) |
|
Common Stock, par value $0.001 |
43145 |
I |
By Activist Investing LLC (1)(2)(3) |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying
Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative
Security |
5. Ownership Form of Derivative Security: Direct (D)
or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Explanation of
Responses: |
(1) |
This Form 3 is filed jointly
by Activist Investing LLC ("Activist Investing") and David E. Lazar
(collectively, the "Reporting Persons"). |
(2) |
Securities of Titan
Pharmaceuticals, Inc. (the "Issuer") beneficially owned directly by
Activist Investing. Mr. Lazar, as the sole member and Chief
Executive Officer of Activist Investing, may be deemed the
beneficial owner of the securities of the Issuer beneficially owned
by Activist Investing. |
(3) |
Each Reporting Person
disclaims beneficial ownership of the securities of the Issuer
reported herein except to the extent of his or its pecuniary
interest therein, and this report shall not be deemed to be an
admission that any Reporting Person is the beneficial owner of such
securities for purposes of Section 16 or for any other
purpose. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Lazar David E.
VILLA 1, 14-43RD STREET
JUMEIRAH 2
DUBAI, C0 00000 |
|
X |
|
|
Activist Investing LLC
1185 AVENUE OF THE AMERICAS, 3RD FLOOR.
NEW YORK, NY 10036 |
|
|
|
Member of 10% owner group |
Signatures
|
/s/ David E. Lazar |
|
7/8/2022 |
**Signature of
Reporting Person |
Date |
Activist Investing LLC, By: /s/ David E. Lazar,
Chief Executive Officer |
|
7/8/2022 |
**Signature of
Reporting Person |
Date |
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
* |
If the form is filed by more than one
reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From May 2023 to Jun 2023
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Jun 2022 to Jun 2023